Summary:
The purpose of this study is to test whether the study medication given as an injection under the skin (subcutaneous) is safe at different dose levels and to find out what effects, good or bad, has on you. The study medication is an antibody (a type of protein) that is made to recognize a receptor on adipose (fat) tissue that may help reduce your resistance to insulin (a hormone your body makes to help you use sugar) as well as increase the amount of energy you release and decrease the number of fat cells you store.
Qualified Participants Must:
• Be between 18 and 75 years of age
•
Have a body mass index (BMI) between 27 kg/m2 and 40 kg/m2
•
Have a currently stable treatment (at least 3 months) for diabetes in any combination of the following lifestyle, metformin, or dipeptidyl peptidase-4 inhibitors (DPP4: Nesina (alogliptin),Januvia (sitagliptin), Onglyza (saxaglitpin), Tradjenta (linagliptin)) only
•
Have a HbA1c greater than 6.8% and less than 9.0%
•
Must not be taking insulin as a form of treatment for type 2 diabetes
Qualified Participants May Receive:
All study procedures and medication will be covered by the sponsor. There will also be compensation for your time and travel.